Skip to content
| Reported maximum average reductions in plasma RNA with selected protease inhibitor combinations (in treament naive/experienced* individuals) |
| SQV |
.6 log |
S. Vella |
| SQV(new formulation) |
1.5 log |
Roche |
| RTV |
1.2-1.9 log |
Abbott |
| IDV |
1.2-2.0 log |
Merck |
| NFV |
1.5 log |
Markowitz |
| SQV+AZT |
1.0 log |
S. Vella |
| SQV+ddC |
.6 log |
Roche NV* |
| SQV+AZT+ddC |
.8 log |
ACTG 229* |
| RTV+AZT |
1.2 log |
Abbott |
| RTV+AZT+ddC |
2.0-2.5 log |
Leibowich |
| IDV+AZT |
1.4-1.5 log |
Merck |
| IDV+AZT+ddl |
2.9 log |
Merck |
| IDV+AZT3TC |
>2.0 log |
Merck 035* |
| NFV+d4T |
2.4-2.6 log |
Chapman |
Back To Top
